Merck's bowel disease drug meets main goal in late-stage trial
- Posted on June 22, 2026
- By Bing News
- 0 Views
- 1 min read
Merck's bowel disease drug meets main goal in late-stage trial
By Christy Santhosh June 22 (Reuters) - Merck said on Monday its experimental drug met the main goal and key secondary goals in a late-stage trial in patients with a type of inflammatory bowel disease. At 12 weeks, the drug, tulisokibart, showed clinical remission in symptoms of ulcerative colitis. Ulcerative colitis is a type of chronic bowel disease that causes long-lasting inflammation and
